The DNER Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal HeLa population with disruption of the human DNER gene. Unlike clonal lines, this heterogeneous pool captures diverse editing events, enabling loss-of-function studies in bulk cultures without the biases of single-cell selection. The product is designed for researchers examining Notch ligand biology in a well-established cancer cell line.
HeLa cells are derived from a human cervical adenocarcinoma and are positive for HPV-18. Viral oncoproteins E6 and E7 degrade p53 and inactivate pRb, respectively, removing key cell cycle checkpoints. This immortalized epithelial line is widely used for its reliable growth, transfectability, and relevance to oncogenic signaling, providing a defined backdrop for gene knockout experiments.
DNER encodes a transmembrane ligand for Notch receptors (NOTCH1?C4). Ligand engagement triggers ADAM10- and ??-secretase-mediated cleavage, releasing the Notch intracellular domain (NICD). NICD complexes with CSL/RBP-J and MAML to activate transcription of targets such as HES1, HEY1, MYC, CCND1, and NF-??B. DNER function is modulated by interactions with other Notch ligands (DLL1, JAG1) and is regulated by neural transcription factors including NEUROG2 and ASCL1. Thus, DNER disruption interrupts a signaling cascade central to differentiation, proliferation, and adhesion.
In the HPV-18-positive HeLa context, where p53 and pRb are compromised, Notch signaling influences cell fate decisions. The DNER polyclonal knockout allows dissection of Notch pathway contributions to proliferation, survival, and migration in cervical adenocarcinoma cells. Because downstream targets include CCND1, MYC, and NF-??B, this model may reveal interactions between DNER and E6/E7-driven oncogenesis. The heterogeneous editing population mimics tumor cell diversity, aiding bulk analysis of pathway dependencies.
Assays such as Western blotting and RT-qPCR can monitor NICD levels and target gene expression (HES1, HEY1). Flow cytometry and immunofluorescence assess DNER surface expression and Notch localization, while luciferase reporters quantify signaling activity. Proliferation and migration assays probe functional outcomes. The polyclonal format is well-suited for drug target validation and population-level studies. For additional information and custom inquiries, please contact Ascent Research.
